Skip to main content
. 2022 Jan 20;25(8):1160–1164. doi: 10.1016/j.neurom.2021.12.001

Table 2.

Effect of COVID-19 and the Lockdown on Patients With SNM Devices.

Variables Canada (Toronto Western Hospital, Toronto, Canada) Kuwait (Al-Amiri Hospital, Kuwait City, Kuwait) Saudi Arabia (King Abdulaziz University, Jeddah, Saudi Arabia) Australia (Austin and Western Health, University of Melbourne, Australia) Total
Treatment of complications during lockdown, if developed
 • None 49 (61%) 16 (80%) 31 (93.9%) 20 (68.9%) 116 (71.6%)
 • Phone 14 (17.5%) 2 (10%) 0 (0%) 8 (27.5%) 24 (14.8%)
 • Turn off 5 (6.25%) 2 (10%) 2 (6%) 1 (3.44%) 10 (7%)
 • ED visit 12 (15%) 0 (0%) 0 (0%) 0 (0%) 12 (7%)
Contact difficulties during lockdown
 • Yes 7 (8.75%) 0 (0%) 3 (9%) 3 (10%) 13 (8%)
 • No 73 (91.25%) 20 (100%) 30 (0.9%) 26 (89.6%) 149 (91.9%)
Follow-up preference
 • Attend 44 (55%) 13 (65%) 10 (30%) 6 (20.6%) 73 (45%)
 • Phone 36 (45%) 7 (35%) 23 (69.6%) 23 (79%) 89 (54.9%)
Lockdown affecting visit
 • Yes 27 (33.75%) 8 (40%) 32 (96.9%) 13 (44.8%) 80 (49%)
 • No 53 (66.25) 12 (60%) 1 (3%) 16 (55%) 82 (50.6%)
Remote programming
 • Yes 71 (88.75%) 17 (85%) 28 (84%) 29 (100%) 145 (89.5%)
 • No 9 (11.25%) 3 (15%) 5 (15%) 0 (0%) 17 (10%)